Key Highlights

  • The pullback comes despite a notable institutional vote of confidence, as Candriam S.C.A. disclosed a new 773,620-share position worth approximately $9.2 million in Q1 filings reported today.
  • Analysts maintain a consensus Buy rating with an average price target of $22.67, well above current trading levels, and the stock remains significantly above its 52-week low of $6.24.
  • Strong analyst support from Morgan Stanley, Needham, and JonesTrading continues to underpin the longer-term bull case even as today's session weighs on near-term momentum.

Trevi Therapeutics (NASDAQ: TRVI) shares are tumbling lower today, underperforming the broader healthcare sector, as investors weigh a mix of company-specific catalysts and broader macro developments.

The pullback comes despite a notable institutional vote of confidence, as Candriam S.C.A. disclosed a new 773,620-share position worth approximately $9.2 million in Q1 filings reported today. Analysts maintain a consensus Buy rating with an average price target of $22.67, well above current trading levels, and the stock remains significantly above its 52-week low of $6.24.

Strong analyst support from Morgan Stanley, Needham, and JonesTrading continues to underpin the longer-term bull case even as today's session weighs on near-term momentum.

Today's move is also unfolding against a broader risk backdrop, as renewed U.S.-Iran hostilities have sent oil prices sharply higher and injected a risk-off tone across equity markets. The healthcare sector, tracked by the XLV ETF, is itself navigating this volatile macro environment, with investors weighing geopolitical headline risk alongside company-specific fundamentals heading into a pivotal earnings season.

Looking ahead, investors will be watching how Trevi Therapeutics's next earnings report and any further analyst commentary shape the stock's trajectory, particularly as markets continue to digest both company-specific catalysts and the broader macro backdrop of geopolitical tension and shifting interest rate expectations.